As the biggest market for pharmaceutical products in Southeast Asia, Indonesia plays a decisive role in mapping the market for pharmaceutical products in the region.Jakarta (ANTARA News) - The Indonesian pharmaceutical industry holds over 50 percent of the share of the Southeast Asian pharmaceutical market, an executive said.
Indonesia, with a population of more than 240 million, represents nearly 50 percent of the Southeast Asian pharmaceutical market, Syamsul Arifin, the president director of publicly-listed pharmaceutical company PT Kimia Farma, said after signing a joint venture agreement with Tianjin Pharmaceutical Group and PT Tigaka Distrindo Perkasa here on Monday.
As the biggest market for pharmaceutical products in Southeast Asia, Indonesia plays a decisive role in mapping the market for pharmaceutical products in the region, he added.
Lu Yan Chang, chairman of the board of Tianjin Pharmaceutical Group Co.Ltd, said the company will soon begin its investment in Indonesia owing to its huge market.
"The (Indonesian) government`s investment policy is very conducive (to investment inflows) and supports the investment climate," he noted.
"We do not rule out the possibility that we will cooperate with other Indonesian companies, state-owned companies in particular," he said.
PT Kimia Farma is teaming up with Tianjin Pharmaceutical Group Co.Ltd and PT Tigaka Distrindo Perkasa (TDP) in building a Rp250 billion pharmaceutical plant in Lippo Cikarang estate, West Java,
Syamsul Arifin said the plant built on 3 hectares of land will produce the `kortikosteroid` drug in the form of injections and hospital solution products.
The plant will be 50 percent owned by Kimia Farma, 4 percent by PT Tigaka Distrindo Perkasa, and 46 percent by Tianjin.
The construction of the plant is expected to be completed by early 2013.(*)
Editor: Heru Purwanto
Copyright © ANTARA 2012
